An Urgent Need for Early Detection

"Lung cancer and liver cancer rank among the top three deadliest cancers globally, primarily due to late diagnoses," states Ilay Marom, co-founder and COO of NaNose Medical. This innovative Israeli startup is determined to flip the script on late-stage cancer detection.

Transforming Diagnostics with Breath Analysis

Founded over five years ago, NaNose Medical aims to revolutionize early diagnosis and screening. Utilizing cutting-edge non-invasive technology that analyzes breath biomarkers, the company’s mission targets critical diseases like liver disease and lung cancer.

Marom emphasizes the importance of early detection. "Everyone knows that early diagnosis saves lives. Yet, for lung and liver cancers, existing screening tests are practically non-existent."

Groundbreaking Technology from the Technion

The foundation of NaNose's technology is rooted in over a decade of research from Israel’s prestigious Technion Institute. Professor Hossam Haick, a key inventor, partnered with the startup’s founders to bring this promising solution to life.

A Driven Team in Crisis

Today, NaNose boasts a dedicated team of 14, led by CEO Orit Marom-Albeck. Their current focus is on commercializing the breath-analysis diagnostic system, a leap forward from outdated tools previously used in medical screenings.

Despite raising $10.5 million—including $6.5 million in equity and around $4 million in grants—the company faced a setback in late 2023 when their fundraising efforts were abruptly interrupted by heightened tensions in the region.

Resilience in the Face of Adversity

Marom recalls the moment their funding plans were derailed: "We received an unforgettable email regarding geographical strategy changes. We found ourselves in a tough spot, but the Israel Innovation Authority and Google stepped up with crucial support, including matching grants and resources."

Addressing MASLD: A Silent Epidemic

NaNose also aims to shine a light on the diagnostic void surrounding Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), affecting about 40% of the global population and leading to severe health issues like cardiovascular disease. With MASLD representing a staggering $103 billion burden on the U.S. healthcare system, the need for effective screening tools is dire.

Innovative Approaches to Lung Cancer Detection

Marom highlights that traditional screening methods like CT scans are largely inaccessible for many potential high-risk patients due to restrictive eligibility criteria. The urgency for a reliable alternative has never been clearer.

A Unique Strategy Inspired by Nature

NaNose’s technology leverages mass spectrometry inspired by human olfactory functions, distinguishing it from competitors who rely on large, cumbersome equipment. Marom explains, "Our method analyzes holistic patterns rather than individual molecules, akin to how we recognize scents like cinnamon without needing to pinpoint their chemical compositions."

Preparing for the Future and Commercial Launch

As NaNose strives for commercial success, Marom draws from his background in the Israeli Navy and studies at Northwestern University. He recognizes that, while technology is essential, financial viability is equally crucial for bringing innovations to market.

"Effective management is key in transforming promising tech into tangible healthcare solutions. Our goal is to provide accessible, efficient screening tools that enhance patient outcomes and journey," concludes Marom.

A Vision for Every Clinic

With aspirations for their technology to be a standard fixture in every physician’s office, NaNose Medical is not merely looking to innovate; they aim to save lives—one breath at a time.